Germany's new early benefit assessment produces its first casualties
This article was originally published in SRA
Executive Summary
Innovative companies are refusing to market some of their new products in Germany because they fear the drugs their products will be compared with for reimbursement purposes under new legislation will result in prices that are too low. It’s time for the assessors to change their approach, say Jörg Schickert and Andreas Schmitz.